Article citationsMore>>

Ramasamy, M.N., Minassian, A.M., Ewer, K.J., Flaxman, A.L., Folegatti, P.M., Owens, D.R., et al. (2021) Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. The Lancet, 396, 1979-1993.
https://doi.org/10.1016/S0140-6736(20)32466-1

has been cited by the following article:

• TITLE: Recurrent Coronary Artery Thrombosis on Triple Anti-Thrombotic Therapy, Is There a Possible Association with ChAdOx1 nCoV-19 Vaccination?

  AUTHORS: Phillip Crane, Voltaire Nadurata, M. Asrar Ul Haq

  KEYWORDS: ST-Elevation Myocardial Infarction, Stent Thrombosis, ChAdOx1 nCoV-19, AstraZeneca, COVID-19, SARS-CoV-2

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.11 No.6, June 30, 2022

  ABSTRACT: Background: Vaccines remain the only viable and safe option to control transmission and minimise disease sequelae during the COVID-19 pandemic. Whilst multiple vaccines are available, evidence has emerged regarding the association between the ChAdOx1 nCoV-19 vaccine, platelets and thrombosis, manifesting in thrombotic thrombocytopaenia. Case Summary: We report a case of recurrent coronary artery thrombosis on triple antithrombotic therapy, namely aspirin, clopidogrel, and continuous intravenous heparin, nine days after the ChAdOx1 nCoV-19 vaccine, in a 63-year-old female with no significant history of cardiovascular disease. Conclusion: This case may suggest that the association between platelets, SARS-CoV-2, the ChAdOx1 nCoV-19 vaccine, and coronary thrombosis may remain incompletely understood and warrants further study. Clinicians should remain on high alert if presented with similar circumstances.